After implementing a process for flagging readmitted radiopharmaceutical therapy patients, it was discovered that major assumptions for these patients were not correct, specifically the magnitude of patients and the location of the readmissions. Data collected from May to December 2024 revealed 501 post-therapy patient encounters out of 1,139 administrations. Analysis showed varying return rates across different radiopharmaceuticals and departments, highlighting the need for updated radiation safety response. Results indicated that most encounters occurred in outpatient settings, with contamination above action levels found in 61% of responses. The study underscores the importance of continuous assessment and collaboration among stakeholders to adapt to new radiopharmaceutical therapies and ensure effective radiation safety practices.
Underwood et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: